Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid
(2002) In Annals of Allergy, Asthma & Immunology 89(2). p.159-165- Abstract
- Background: Symptoms of seasonal allergic rhinitis may vary greatly. Hence, for research purposes, there is a need for disease-like models of allergic rhinitis. In a preliminary study, involving 7 days' challenge with allergen, promising symptom consistency was obtained and dose-response to a glucocorticosteroid could, in part, be demonstrated. Objective: To establish this model of seasonal allergic rhinitis and test the hypothesis that mometasone furoate is more potent than budesonide as an antirhinitis drug. Methods: Thirty-eight patients with seasonal allergic rhinitis received treatment with spray-formulations of placebo, budesonide 64 kg, budesonide 256 mug, and mometasone furoate 200 mug in a double-blind, crossover design. After 3... (More)
- Background: Symptoms of seasonal allergic rhinitis may vary greatly. Hence, for research purposes, there is a need for disease-like models of allergic rhinitis. In a preliminary study, involving 7 days' challenge with allergen, promising symptom consistency was obtained and dose-response to a glucocorticosteroid could, in part, be demonstrated. Objective: To establish this model of seasonal allergic rhinitis and test the hypothesis that mometasone furoate is more potent than budesonide as an antirhinitis drug. Methods: Thirty-eight patients with seasonal allergic rhinitis received treatment with spray-formulations of placebo, budesonide 64 kg, budesonide 256 mug, and mometasone furoate 200 mug in a double-blind, crossover design. After 3 days' treatment, individualized nasal allergen-challenges were administered daily for 7 days while the treatment continued. Nasal symptoms and peak inspiratory flow (PIF) were recorded. Results: During the last 3 days of allergen challenge without active treatment, consistent around-the-clock symptoms were recorded and recordings during these days were used in the analysis. With few exceptions the active treatments reduced nasal symptoms and improved nasal PIF (P values <0.001 to 0.05). Budesonide caused dose-dependent improvements in evening symptoms, morning nasal PIF, and nasal PIF recorded 10 minutes after allergen-challenge (P values <0.05). Budesonide 256 mug produced greater improvement than mometasone furoate 200 mug for nasal PIF 10 minutes after allergen-challenge (P < 0.05). Conclusion: The present allergen challenge method, producing consistent symptoms and nasal PIF data, emerges as a model of seasonal allergic rhinitis well suited for exploring potency and efficacy of drug intervention. The present data do not support the view that mometasone furoate is a more potent antirhinitis drug than budesonide. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/331133
- author
- Ahlström-Emanuelsson, Cecilia LU ; Persson, Carl LU ; Svensson, Christer LU ; Andersson, Morgan LU ; Hosszu, Z ; Akerlund, A and Greiff, Lennart LU
- organization
- publishing date
- 2002
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Allergy, Asthma & Immunology
- volume
- 89
- issue
- 2
- pages
- 159 - 165
- publisher
- Elsevier
- external identifiers
-
- wos:000177545200011
- pmid:12197572
- scopus:0036706887
- ISSN
- 1081-1206
- language
- English
- LU publication?
- yes
- id
- bf9d0465-e04b-401f-9b97-b6a196cf53c0 (old id 331133)
- alternative location
- http://openurl.ingenta.com/content?genre=article&issn=1081-1206&volume=89&issue=2&spage=159&epage=165
- date added to LUP
- 2016-04-01 11:55:12
- date last changed
- 2022-03-28 17:39:13
@article{bf9d0465-e04b-401f-9b97-b6a196cf53c0,
abstract = {{Background: Symptoms of seasonal allergic rhinitis may vary greatly. Hence, for research purposes, there is a need for disease-like models of allergic rhinitis. In a preliminary study, involving 7 days' challenge with allergen, promising symptom consistency was obtained and dose-response to a glucocorticosteroid could, in part, be demonstrated. Objective: To establish this model of seasonal allergic rhinitis and test the hypothesis that mometasone furoate is more potent than budesonide as an antirhinitis drug. Methods: Thirty-eight patients with seasonal allergic rhinitis received treatment with spray-formulations of placebo, budesonide 64 kg, budesonide 256 mug, and mometasone furoate 200 mug in a double-blind, crossover design. After 3 days' treatment, individualized nasal allergen-challenges were administered daily for 7 days while the treatment continued. Nasal symptoms and peak inspiratory flow (PIF) were recorded. Results: During the last 3 days of allergen challenge without active treatment, consistent around-the-clock symptoms were recorded and recordings during these days were used in the analysis. With few exceptions the active treatments reduced nasal symptoms and improved nasal PIF (P values <0.001 to 0.05). Budesonide caused dose-dependent improvements in evening symptoms, morning nasal PIF, and nasal PIF recorded 10 minutes after allergen-challenge (P values <0.05). Budesonide 256 mug produced greater improvement than mometasone furoate 200 mug for nasal PIF 10 minutes after allergen-challenge (P < 0.05). Conclusion: The present allergen challenge method, producing consistent symptoms and nasal PIF data, emerges as a model of seasonal allergic rhinitis well suited for exploring potency and efficacy of drug intervention. The present data do not support the view that mometasone furoate is a more potent antirhinitis drug than budesonide.}},
author = {{Ahlström-Emanuelsson, Cecilia and Persson, Carl and Svensson, Christer and Andersson, Morgan and Hosszu, Z and Akerlund, A and Greiff, Lennart}},
issn = {{1081-1206}},
language = {{eng}},
number = {{2}},
pages = {{159--165}},
publisher = {{Elsevier}},
series = {{Annals of Allergy, Asthma & Immunology}},
title = {{Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid}},
url = {{http://openurl.ingenta.com/content?genre=article&issn=1081-1206&volume=89&issue=2&spage=159&epage=165}},
volume = {{89}},
year = {{2002}},
}